Member Info for gotabesirius

Time will tell my friend. Either way it'll go higher... Just a matter of when not if

Yes, and I have reached my conclusion, after speaking to several others much more connected....

To the absolute contrary

I don't believe it's Link, it's simply placing stock being spun out.... Relax and let the market do it's thing

It's none of the aforementioned.... But nothing to worry about. In two weeks it'll be back in the teens!

Absolutely, knowing you have antibodies at point of sale especially is huge. All front line customers service based should be provided with a test as part of their health and safety assessment!

Haha nice try!!!

Why do you presume link are selling? Considering we've just had a fund raise at 11p I don't think you need dig much further into the price action!

What's happening in Iran Rudey? Thanks

As usual we have a down day and the idiots arrive! Company is undervalued by probably a factor of at least 2. However, this does not account for the 49% stake in the non core asset which is Imutex. If we go for a middle of the road valuation of £300m then orph is sat on a £145m windfall, twice the current market cap. Will any major pharmaceutical company want one of only two phase III ready universal flu vaccines......? I think we know the answer to this! Sit tight and ride the churn

So why are you still here?

Many thanks

When are these shares submitted to the market? Thanks

That's about the nuts and bolts of it. Business is probably worth £200m... Then add in Imutex

Placing stock being churned.... You need to look at the bigger picture. Volume massive and newsflow will flush out any sellers

Newsflow is stacked for this share over the coming days, weeks & months. If Imutex is sold you risk missing out on a monumental pay day. Imho Imutex is worth many multiples of current orph market cap, this is what new investors should be researching. Testing is chicken feed in comparison.

Long and strong from sub 6p entry and probably only half way through the journey here!

One word... 'debt'

As those that's been here a while will know, the investment case is fascinating. The fundraise has massively derisked the Company at current price. Given current situation with Covid-19 and the race for a vaccine the Company will be inundated with huge pharmaceutical companies testing their vaccines using HVIVO challenge study model to prove if if it works. The PR around this company later this summer will be huge. It'll be in all the papers and news.... PR drives the small cap market, how far this will push the share price is open to question, especially with other major pieces of news and contracts which should land over coming weeks and months. However, I'll be amazed if the price doesn't get pushed north of 30p or to around £200m valuation which will still only be around 2x forward earning - which in the pharma space during a pandemic is cheap. Time to sit back, relax and enjoy the summer and see where this goes.

Bang on! Sit back and watch the value increase

Just buy open market